| Literature DB >> 34889236 |
Zhonggui Xiong1, Jiong Yan1, Shuhua Shi2.
Abstract
ABSTRACT: This study analyzed the Val158Met polymorphisms of the catechol-O-methyltransferase (COMT) gene and serum concentrations of catecholaminergic neurotransmitters in attention deficit hyperactivity disorder (ADHD) children and adolescents.All the subjects (180 paired ADHD and non-ADHD children and adolescents) were genotyped for the Val158Met polymorphisms of the COMT gene, and determined by the difference of dopamine and noradrenalin from a 1:1 paired case-control study.The frequencies of methionine (A)/A, valine (G)/A, and G/G were 51.67%, 41.11%, and 7.22% in the case group, and 62.22%, 31.11%, and 6.67% in the control group. There was a significant difference in the distribution of all genotypes of the COMT gene between the 2 groups (odds ratio = 1.85, 95% confidence interval: 1.62-2.08; χ2 = 7.80, P < .05). The serum concentrations of dopamine and noradrenalin were 1.42 ± 0.34 ng/mL and 177.70 ± 37.92 pg/mL in the case group, and 1.94 ± 0.42 ng/mL and 206.20 ± 42.45 pg/mL in the control group. There were the significant differences in the levels of dopamine and noradrenalin between the 2 groups (dopamine: t = 4.30, P < .01; noradrenalin: t = 2.24, P < .05).Our study suggested that the Val158Met polymorphisms of the COMT gene and serum concentrations of catecholaminergic neurotransmitters were associated with ADHD children and adolescents.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34889236 PMCID: PMC8663844 DOI: 10.1097/MD.0000000000027867
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Distribution of all alleles of the COMT gene between the case and control groups.
| Frequency of alleles (%) | ||||||
| Group | n | A (Met) | G (Val) | OR (95%CI) | χ2 |
|
| Case | 180 | 260 (72.22) | 100 (27.78) | 0.74 (0.58–0.90) | 2.96 | >.05 |
| Control | 180 | 280 (77.78) | 80 (22.22) | |||
Distribution of all genotypes of the COMT gene between the case and control groups.
| Frequency of genotypes (%) | |||||||
| Group | n | A/A (Met/Met) | G/A (Val/Met) | G/G (Val/Val) | OR (95%CI) | χ2 |
|
| Case | 180 | 93 (51.67) | 74 (41.11) | 13 (7.22) | 1.85 (1.62–2.08) | 7.80 | <.05 |
| Control | 180 | 112 (62.22) | 56 (31.11) | 12 (6.67) | |||
Serum concentrations of catecholaminergic neurotransmitters between the case and control groups.
| Neurotransmitters | Case (n = 180, mean ± SD) | Control (n = 180, mean ± SD) | t |
|
| Dopamine (ng/mL) | 1.42 ± 0.34 | 1.94 ± 0.42 | 4.30 | <.01 |
| Noradrenalin (pg/mL) | 177.70 ± 37.92 | 206.20 ± 42.45 | 2.24 | <.05 |
Serum concentrations of catecholaminergic neurotransmitters in the predominately inattentive presentation between the case and control groups.
| Neurotransmitters | Case (n = 60, mean ± SD) | Control (n = 60, mean ± SD) | t |
|
| Dopamine (ng/mL) | 1.70 ± 0.42 | 2.05 ± 0.49 | 2.11 | <.05 |
| Noradrenalin (pg/mL) | 192.77 ± 30.67 | 231.50 ± 52.82 | 2.14 | <.05 |
Serum concentrations of catecholaminergic neurotransmitters in the combined presentation between the case and control groups.
| Neurotransmitters | Case (n = 60, mean ± SD) | Control (n = 60, mean ± SD) | t |
|
| Dopamine (ng/mL) | 1.39 ± 0.31 | 2.10 ± 0.50 | 3.28 | <.01 |
| Noradrenalin (pg/mL) | 177.00 ± 52.38 | 250.00 ± 47.31 | 2.69 | <.01 |
Serum concentrations of catecholaminergic neurotransmitters in the predominately hyperactive presentation between the case and control groups.
| Neurotransmitters | Case (n = 60, mean ± SD) | Control (n = 60, mean ± SD) | t |
|
| Dopamine (ng/mL) | 1.51 ± 0.51 | 2.14 ± 0.47 | 2.32 | <.05 |
| Noradrenalin (pg/mL) | 187.50 ± 30.57 | 240.57 ± 49.87 | 2.26 | <.05 |